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At present, it is not known whether undetectable plasma viremia corresponds to an absence of
human immunodeficiency virus type 1 (HIV-1) replication in lymphoid tissues. This issue has been
explored in 11 subjects with primary HIV-1 infection treated with zidovudine plus didanosine by
evaluating virologic markers in blood and lymphoid tissues 9–18 months after initiation of treatment.
These markers include plasma viremia, measured with a sensitive assay with a detection limit of 20
HIV-1 RNA copies/mL, infectious virus titers and proviral DNA in lymph node mononuclear cells,
and HIV-1 RNA in lymphoid tissue. Five subjects had plasma viremia 20 copies/mL and showed no
evidence of viral replication in lymphoid tissue. Six subjects had both detectable plasma viremia and
evidence of HIV-1 RNA in lymphoid tissue. The results indicate that absence of detectable HIV RNA
in lymphoid tissue is associated with viremia levels of HIV-1 RNA 20 copies/mL.
The primary goal of combined antiviral therapy is to achieve lymphoid tissue biopsies were obtained from lymph nodes,
tonsils, and adenoids, and viral replication was assessed incomplete suppression of viral replication and possibly eradica-
tion of human immunode®ciency virus type 1 (HIV-1). Re- parallel in blood and lymphoid tissues.
cently, several studies showed a dramatic reduction of viremia
to levels below the detection limit of currently used assays
(i.e., 500±200 HIV-1 RNA copies/mL of plasma) in HIV-1± Patients and Methods
infected subjects receiving combined antiviral therapy [1±3].
Study population. All subjects with primary HIV-1 infectionHowever, the recent development of a sensitive assay for the
referred to us between January 1995 and March 1996 were offereddetermination of plasma viremia, with a lower detection limit
an open-label therapeutic regimen with zidovudine (250 mg twiceof 20 copies/mL, demonstrated that 45% of plasma samples
a day) and didanosine (200 mg twice a day) [8]. All subjectswith viremia 200 copies/mL, had 20 HIV-1 RNA copies/
experienced an acute retroviral syndrome at the time of or in the
mL of plasma [4].
month preceding initiation of antiviral therapy, except 1 subject
To date, it is dif®cult to assess whether the absence of detect- who was included 2 months after the onset of the acute retroviral
able HIV-1 RNA in plasma re¯ects the situation in other ana- syndrome. The subjects were Caucasians; 7 were male and 4 fe-
tomic compartments, such as lymphoid tissue, which is the male, with a mean age at study entry of 37 years (range, 26±54).
primary site for viral spreading and replication [5±7]. There- HIV-1 infection was acquired through homosexual contacts in 6
subjects and heterosexual contacts in 5. At 9±18 months afterfore, it seems crucial to compare the levels of viral replication
initiation of treatment, excisional lymph node biopsies were per-in blood and lymphoid tissue and to identify plasma viremia
formed in the inguinal area in 11 subjects; tonsil and adenoidlevels that correspond to undetectable viral replication in
biopsies were collected in parallel in 3 of them.lymphoid tissue.
HIV-1 RNA assay. Viremia levels were determined in batchesTo address these issues, 11 subjects with primary HIV-1
using EDTA-treated plasma samples, stored in aliquots at 0757C,infection receiving combination therapy [8] were enrolled in a
using the Amplicor HIV-1 Monitor test (Roche, Basel, Switzer-
prospective study. At 9±18 months after treatment initiation,
land) according to the manufacturer's instructions, with a detection
limit of 200 HIV-1 RNA copies/mL. Samples with viremia
200 copies/mL were retested using a ``boosted'' modi®cation
of the Amplicor HIV Monitor test with a detection limit of 20
Received 16 September 1997; revised 8 January 1998. HIV-1 RNA copies/mL [4].
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Quanti®cation of proviral DNA. The proviral DNA concentra-1997.
tion associated with lymph node mononuclear cells (LNMC) andInformed consent was obtained from all patients in the study, and the proto-
col was approved by the Institutional Review Board. peripheral blood mononuclear cells (PBMC) was measured in du-
Financial support: Swiss National AIDS Research Program (3239.041951.94). plicate as previously reported [9]. The input of cellular DNA was
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of the assay was 1±3 HIV-1 DNA copies/2.5 mg of DNA. Samples
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In situ hybridization. In situ hybridization for the detection of Results
HIV-1 RNA was performed on paraf®n-embedded tissue sections HIV-1 replication in blood. Viral replication in blood was
using RNA probes that comprised 90% of the HIV-1 genome, as
evaluated, at the time of lymph node collection, via the determi-
previously described [5]. The number of individual cells express-
nation of plasma viremia. Five of 11 subjects (subjects 1±5;ing HIV-1 RNA were quanti®ed by ®rst determining the area of
table 1) had levels of plasma viremia20 HIV-1 RNA copies/the biopsy section, using computerized planimetry, followed by
mL. Subjects 6±8 had levels of plasma viremia just above thecounting the number of HIV-1 RNA±expressing cells in the biopsy
detection limit, ranging between 22 and 25 copies/mL, whereassection, using a dark®eld microscope at 1100 magni®cation. The
plasma viremia was 200 copies/mL in subjects 9±11 (tablesensitivity of the in situ hybridization procedure was determined
1). The sensitive assay allowed the detection of viremia inby constructing a standard containing a known number of HIV-1
virions and was found to correspond to 13 virus particles (5 silver subjects 6±10, in whom viremia levels were below the detec-
grains). HIV-1 RNA±expressing cells were reported as the number tion limit (500 to 200 HIV-1 RNA copies/mL) of the commer-
of cells per 10 mm2. cial assay. Figure 1A shows the kinetics of plasma viremia in
Infectious HIV-1 titers. Suspensions of LNMC were ob- the 5 subjects with 20 HIV-1 RNA copies/mL at the time of
tained after mincing lymph node tissue with a scalpel, teasing lymph node collection. All 5 had plasma viremia of 20 cop-
out the cells, and isolating them by ®coll-hypaque gradient cen- ies/mL at 6 months after initiation of combination therapy.
trifugation. Aliquots of 5 1 106 cells in 20% fetal calf serum and
HIV-1 replication in lymph nodes. Viral replication in
10% dimethyl sulfoxide were stored in liquid nitrogen. Cellular
lymph nodes was evaluated by in situ hybridization of cell-infectious titers were determined using quantitative cell micro-
associated HIV-1 RNA and by determination of infectious virusculture [10]. Six dilutions of LNMC, depleted of CD8 cells,
titers in suspensions of LNMC (table 1). Subjects 1±6 showedstarting at a concentration of 106 LNMC, were cocultivated in
no evidence of cells expressing HIV-1 RNA. Cells expressingduplicate with 106 phytohemagglutinin (PHA)-stimulated CD8
HIV-1 RNA were, however, detected in subjects 7±11 (®gurecell±depleted PBMC from HIV-negative donors. Half of the
culture medium was replaced with fresh medium twice a week. 2). A second lymph node biopsy was performed in subjects 1
Fresh uninfected PHA-stimulated PBMC were added to the cul- and 2 at 7 months after the ®rst biopsy. Like the ®rst lymph
ture once a week. On days 14 and 21, culture ¯uid from each node analyzed, the second had no detectable cells expressing
well was tested for HIV-1 p24 antigen level using a commercial HIV-1 RNA. Infectious virus was recovered from subjects 6,
ELISA (Abbott Laboratories, North Chicago). Results are ex- 7, and 9±11. The titers of infectious virus were very low in
pressed as infectious units per million cells. subjects 6 and 7 and higher in subjects 9±11 (table 1). No
Immunologic parameters. CD3, CD4, and CD8 lymphocyte
evidence of active viral replication as assessed by coculture
counts were determined on fresh material in lymph nodes and
was found in subjects 1±5, whereas virus was isolated in sub-blood by ¯ow cytometry (Coulter EPICS IV; Instrumente Gesell-
jects 6±11 (table 1). Failure to detect HIV-1 replication inschaft, Basel, Switzerland) using ¯uoresceinated DAKO-CD3,
lymph nodes was con®ned to subjects 1±5, who had plasmaDAKO-CD8, and R-Phycoerythrin DAKO-CD4 (Dako, Glos-
viremia of 20 copies/mL.trup, Denmark). To minimize variations linked to ¯uctuations
HIV-1 RNA associated with follicular dendritic cells (FDC).in total lymphocyte counts, results were expressed as the CD4/
CD8 ratio. Previous studies showed that the diffuse HIV-1 RNA hybrid-
Table 1. Virus burden and CD4/CD8 cell ratio in blood and lymph nodes after 9 months of antiviral therapy.
Lymph nodes
Blood In situ hybridization
Time, HIV RNA, DNA, CD4/CD8 FDC-associated HIV RNA±positive DNA, Viral culture, CD4/CD8
Patients months copies/mL copies/106 cell ratio HIV RNA cells/10 mm2 copies/106 IU/106 LNC cell ratio
1 11 20 3 1.57 Absent ND 61 0 4.00
2 13 20 16 1.03 Present ND 317 0 5.60
3 14 20 3 1.32 Absent ND 37 0 2.59
4 12 20 3 0.87 Absent ND 3 0 4.92
5 10 20 3 1.03 Present ND 24 0 4.64
6 10 22 3 2.22 Present ND 63 5 3.53
7 11 25 3 0.97 Present 0.66 42 5 2.63
8 11 25 3 1.32 Absent 0.66 3 0 5.00
9 10 185 16 0.67 Present 0.66 79 100 2.32
10 18 440 50 0.73 Present 3.4 4433 625 2.38
11 9 32,790 290 0.68 Present 3.4 11,336 3125 1.44
NOTE. ND, not detected; FDC, follicular dendritic cells; IU, infectious units; LNC, lymph node cells.
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Figure 1. Viremia (A) and proviral DNA
(B) levels in 5 subjects treated with zido-
vudine plus didanosine with no detectable
viral replication in lymph nodes. Patient
nos. (P1±P5) indicated in A correspond to
those reported in table 1. Detection limit in
dashed line corresponds to 20 HIV-1 RNA
copies/mL of plasma (A) and 3 proviral
DNA copies/106 peripheral blood mononu-
clear cells (PBMC) (B).
ization signal associated with germinal centers corresponded ever, only traces of HIV-1 trapped in the FDC network were
observed in tonsil tissue (data not shown) compared with theto HIV-1 virions trapped in the FDC network [5±7]. In our
study, trapping of HIV-1 in the FDC network was either absent presence of both trapped virions and individual cells expressing
HIV-1 RNA in lymph node tissue (table 1).(subjects 1, 3, and 4) or present in traces (subjects 2 and 5) in
subjects with plasma viremia of20 copies/mL (table 1, ®gure Proviral HIV-1 DNA. Proviral HIV-1 DNA concentrations
in blood were 3 copies/106 PBMC in 4 of 5 subjects with2). In subject 2, trapping of HIV-1 was no longer detected
in the second lymph node biopsy, performed 7 months later. plasma viremia of 20 HIV-1 RNA copies/mL. Among the
subjects with viremia of 20 copies/mL, proviral DNA inTrapping of HIV-1 in the FDC network was present in all but
1 of the subjects with plasma viremia of 20 copies/mL (ta- blood was below the detection limit in subjects 6±8, with
viremia of 20±30 copies/mL, whereas the highest levels wereble 1).
HIV-1 distribution in lymph nodes, tonsils, and adenoids. observed in subjects 9±11, with viremia of 30 copies/mL
(table 1). Proviral DNA was detected in lymph nodes of allBiopsies of tonsils and adenoids were performed in subjects 4
and 9 at the same time as the lymph node biopsy and in subject subjects except 4 and 8 (table 1). Proviral DNA was signi®-
cantly higher (6- to 39-fold) in LNMC than in PBMC (tableP2 at the time of the second lymph node biopsy. No differences
in HIV-1 distribution, including trapping of virions and cell 1). Kinetics of proviral DNA decay in PBMC from subjects
1±5 are shown in ®gure 1B. Four of 5 subjects had proviralexpression of HIV-1 RNA, were observed in subjects 2 or 4
in the various lymphoid tissues analyzed. In subject P9, how- DNA levels of 3 copies/106 PBMC within 9 months. The
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Figure 2. Sections of lymph node tissue from 4 subjects who received antiviral therapy with zidovudine plus didanosine at time of primary
HIV infection and who had evidence of persistent viral replication and/or follicular dendritic cell (FDC)±associated deposits. Dark®eld images
of in situ hybridization for HIV RNA are shown. Location of HIV RNA is indicated by silver grains, which appear as white dots. A±C,
Hybridization signal is localized over germinal centers; typical examples of different degrees of virus trapping in FDC are represented in A
(very low), B (low), and C (intermediate). D, Typical example of hybridization signal localized in 5 isolated cells expressing HIV-1 RNA.
decrease of proviral DNA was slower than that of viremia HIV-1 RNA copies/mL of plasma [1 ± 3]. However, HIV-1
replication in lymphoid tissue was detected in subjects with(®gure 1).
plasma viremia below 500 to 200 copies/mL [11, 12]. TheLymphocyte markers. CD4/CD8 ratios in lymph nodes and
results of the present study, performed by using a sensitiveblood are reported in table 1. All subjects, regardless of plasma
assay with a detection limit of 20 HIV-1 RNA copies/mL,viremia levels, had a higher CD4/CD8 ratio in lymph nodes
indicate that the plasma viremia levels corresponding to un-than in blood. However, no signi®cant correlation was observed
detectable viral replication in lymphoid tissue, includingbetween the CD4/CD8 ratios in lymph nodes and blood. Sub-
lymph nodes, adenoids, and tonsils, are generally 20 cop-jects with no evidence of viral replication in lymph nodes
ies/mL. When detectable, viral replication in lymphoid tissuetended to have a higher CD4/CD8 ratio in lymphoid tissue
appears to be associated with plasma viremia 20 copies/(median, 4.64 vs. 2.51; P  .07).
mL. It is important to underscore, however, that levels of
plasma viremia 20 copies/mL and undetectable viral repli-
Discussion
cation in lymphoid tissue do not necessarily re¯ect complete
Viremia levels in blood are routinely measured by com- suppression of viral replication, since the techniques used
mercial assays with a lower detection limit of 500 to 200 are limited by their sensitivity and the size of the sample
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